Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1991 Nov;86(2):224–228. doi: 10.1111/j.1365-2249.1991.tb05800.x

The effect of FK506 and cyclosporin A on antigen-induced arthritis.

A Blackham 1, R J Griffiths 1
PMCID: PMC1554129  PMID: 1718639

Abstract

FK506 and cyclosporin A inhibited the development of antigen-induced arthritis in the rat and rabbit. FK506 was five times more potent than cyclosporin A in the rat and approximately 20 times more potent in the rabbit. FK506 was effective in both species if administered either from the day of intra-articular administration of antigen or when the arthritis was established. In the rabbit, arthritis returned when administration of FK506 was stopped. FK506 (10 mg/kg/day) caused renal damage which was not observed at a dose of 2.5 mg/kg/day. Both of these doses were equally effective at inhibiting the arthritis. The conclusion from these studies is that FK506 is a more effective anti-arthritic agent than cyclosporin A and that a pronounced therapeutic effect can be achieved at non-toxic doses of the drug.

Full text

PDF
224

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arita C., Hotokebuchi T., Miyahara H., Arai K., Sugioka Y., Kaibara N. Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. Clin Exp Immunol. 1990 Dec;82(3):456–461. doi: 10.1111/j.1365-2249.1990.tb05471.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Billingham M. E. Models of arthritis and the search for anti-arthritic drugs. Pharmacol Ther. 1983;21(3):389–428. doi: 10.1016/0163-7258(83)90062-1. [DOI] [PubMed] [Google Scholar]
  3. Borel J. F., Feurer C., Gubler H. U., Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976 Jul;6(4):468–475. doi: 10.1007/BF01973261. [DOI] [PubMed] [Google Scholar]
  4. Brackertz D., Mitchell G. F., Vadas M. A., Mackay I. R. Studies on antigen-induced arthritis in mice. III. Cell and serum transfer experiments. J Immunol. 1977 May;118(5):1645–1648. [PubMed] [Google Scholar]
  5. Inamura N., Hashimoto M., Nakahara K., Aoki H., Yamaguchi I., Kohsaka M. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol. 1988 Jan;46(1):82–90. doi: 10.1016/0090-1229(88)90008-6. [DOI] [PubMed] [Google Scholar]
  6. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987 Sep;40(9):1249–1255. doi: 10.7164/antibiotics.40.1249. [DOI] [PubMed] [Google Scholar]
  7. Ochiai T., Nagata M., Nakajima K., Sakamoto K., Asano T., Isono K. Prolongation of canine renal allograft survival by treatment with FK-506. Transplant Proc. 1987 Oct;19(5 Suppl 6):53–56. [PubMed] [Google Scholar]
  8. Pettipher E. R., Henderson B. The relationship between cell-mediated immunity and cartilage degradation in antigen-induced arthritis in the rabbit. Br J Exp Pathol. 1988 Feb;69(1):113–122. [PMC free article] [PubMed] [Google Scholar]
  9. Starzl T. E., Todo S., Fung J., Demetris A. J., Venkataramman R., Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989 Oct 28;2(8670):1000–1004. doi: 10.1016/s0140-6736(89)91014-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Stuart J. M., Cremer M. A., Townes A. S., Kang A. H. Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med. 1982 Jan 1;155(1):1–16. doi: 10.1084/jem.155.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Takagishi K., Yamamoto M., Nishimura A., Yamasaki G., Kanazawa N., Hotokebuchi T., Kaibara N. Effects of FK-506 on collagen arthritis in mice. Transplant Proc. 1989 Feb;21(1 Pt 1):1053–1055. [PubMed] [Google Scholar]
  12. Tocci M. J., Matkovich D. A., Collier K. A., Kwok P., Dumont F., Lin S., Degudicibus S., Siekierka J. J., Chin J., Hutchinson N. I. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol. 1989 Jul 15;143(2):718–726. [PubMed] [Google Scholar]
  13. Tugwell P., Bombardier C., Gent M., Bennett K. J., Bensen W. G., Carette S., Chalmers A., Esdaile J. M., Klinkhoff A. V., Kraag G. R. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet. 1990 May 5;335(8697):1051–1055. doi: 10.1016/0140-6736(90)92630-z. [DOI] [PubMed] [Google Scholar]
  14. van Rijthoven A. W., Dijkmans B. A., Goei The H. S., Hermans J., Montnor-Beckers Z. L., Jacobs P. C., Cats A. Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Ann Rheum Dis. 1986 Sep;45(9):726–731. doi: 10.1136/ard.45.9.726. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES